nach oben

Current Diabetes Reports

Erschienen in:

29.02.2024 | REVIEW

Diabetes Technology in People with Type 2 Diabetes: Novel Indications

verfasst von: Shubham Agarwal, Rodolfo J. Galindo, Amy V. Shah, Marconi Abreu

Erschienen in: Current Diabetes Reports | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Diabetes technology has been continuously evolving. Current versions of continuous glucose monitors (CGM) use minimally invasive designs, monitor glucose values with high accuracy, and can be used to guide insulin dosing. Extensive evidence supports the use of diabetes technology for monitoring and insulin administration in people with type 1 diabetes. However, there is emerging evidence for people with type 2 diabetes. In this review, we present the different technological devices used to monitor glucose and deliver insulin and the evidence supporting their use in people with type 2 diabetes.

Recent Findings

The use of CGMs in people with type 2 diabetes treated with insulin or non-insulin therapies has been associated with improvements in glycemic control and time spent in hypoglycemia. Smart insulin pens and smart connected devices are options to track compliance and guide insulin delivery in people who do not require insulin pump therapy. Mechanical patch pumps can be used to reduce the burden of multiple daily insulin injections. Automated insulin delivery algorithms improve glycemic control without an increase in hypoglycemia.

Summary

The use of technology in the management of type 2 diabetes generates glycemic data previously inaccessible, reduces barriers for insulin initiation, improves glycemic control, tracks adherence to therapy, and improves user satisfaction.

UK Prospective Diabetes Study (UKPDS). Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53. https://doi.org/10.1016/S0140-6736(98)07019-6.CrossRef

Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39. https://doi.org/10.1056/NEJMoa0808431.CrossRefPubMed

ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 2008;358(24):2560–2572 https://doi.org/10.1056/NEJMoa0802987

Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–30. https://doi.org/10.1016/S0140-6736(10)60576-4.CrossRefPubMedPubMedCentral

Galindo RJ, Trujillo JM, Low Wang CC, McCoy RG. Advances in the management of type 2 diabetes in adults. BMJ Med. 2023;2(1):e000372. https://doi.org/10.1136/bmjmed-2022-000372.CrossRefPubMedPubMedCentral

Lingvay I, Agarwal S. A revolution in obesity treatment. Nat Med. 2023;29(10):2406–8. https://doi.org/10.1038/s41591-023-02538-7.CrossRefPubMed

Fang M, Wang D, Coresh J, Selvin E. Trends in diabetes treatment and control in US adults 1999–2018 N Engl J Med. 2021; 384(23):2219–2228 https://doi.org/10.1056/NEJMsa2032271

• Galindo RJ, Aleppo G. Continuous glucose monitoring: the achievement of 100 years of innovation in diabetes technology Diabetes Res Clin Pract. 2020;170:108502. https://doi.org/10.1016/j.diabres.2020.108502. This article covers the salient advances in CGM technology over time and provides tips on implementation of CGM in the medical office.

Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile. J Diabetes Sci Technol. 2013;7(2):562–78. https://doi.org/10.1177/193229681300700234.CrossRefPubMedPubMedCentral

10.

Das SK, Nayak KK, Krishnaswamy PR, et al. Review—electrochemistry and other emerging technologies for continuous glucose monitoring devices. ECS Sensors Plus. 2022;1(3) https://doi.org/10.1149/2754-2726/ac7abb

11.

Heinemann L, Schoemaker M, Schmelzeisen-Redecker G, et al. Benefits and limitations of MARD as a performance parameter for continuous glucose monitoring in the interstitial space. J Diabetes Sci Technol. 2020;14(1):135–50. https://doi.org/10.1177/1932296819855670.CrossRefPubMed

12.

Puhr S, Derdzinski M, Welsh JB, Parker AS, Walker T, Price DA. Real-world hypoglycemia avoidance with a continuous glucose monitoring system’s predictive low glucose alert. Diabetes Technol Ther. 2019;21(4):155–8. https://doi.org/10.1089/dia.2018.0359.CrossRefPubMedPubMedCentral

13.

Dexcom G6 User Guide. https://s3-us-west-2.amazonaws.com/dexcompdf/Downloads+and+Guides+Updates/LBL017451+Using+Your+G6%2C+G6%2C+UK%2C+EN%2C+mmol.pdf. Accessed 20 Nov 2023

14.

Dexcom G7 User Guide. https://s3.us-west-2.amazonaws.com/dexcompdf/Downloads+and+Guides+Updates/AW00046-05+UG+G7+OUS+en+MMOL.pdf. Accessed 20 Nov 2023

15.

FreeStyle Libre 2 User Manual. https://freestyleserver.com/Payloads/IFU/2023/q3/ART48230-001_rev-A-web.pdf. Accessed 20 Nov 2023

16.

FreeStyle Libre 3 User Manual. https://freestyleserver.com/payloads/ifu/2023/q3/ART41641-001_rev-A-web.pdf. Accessed 20 Nov 2023

17.

Guardian Sensor 3 User Guide. https://www.medtronicdiabetes.com/sites/default/files/library/download-library/user-guides/Guardian_Sensor_3_User_Guide_Jun-2023.pdf. Accessed 20 Nov 2023

18.

Guardian Sensor 4 User Guide. https://www.medtronicdiabetes.com/sites/default/files/library/download-library/user-guides/Guardian_4_sensor_user_guide.pdf Accessed 20 Nov 2023.

19.

Medtronic News. Medtronic Diabetes announces CE Mark for new Simplera™ CGM with disposable all-in-one design. https://news.medtronic.com/2023-09-21-Medtronic-Diabetes-announces-CE-Mark-for-new-Simplera-TM-CGM-with-disposable-all-in-one-design. Accessed 20 Nov 2023

20.

Eversense E3 User Guide. https://www.eversensediabetes.com/wp-content/uploads/LBL-6002-01-001-Rev-B_Eversense-E3-User-Guide_mgdL_R1.pdf. Accessed November 20, 2023.

21.

Reiterer F, Polterauer P, Schoemaker M, et al. Significance and reliability of MARD for the accuracy of CGM systems. J Diabetes Sci Technol. 2017;11(1):59–67. https://doi.org/10.1177/1932296816662047.CrossRefPubMed

22.

Roussel R, Riveline JP, Vicaut E, et al. Important drop in rate of acute diabetes complications in people with type 1 or type 2 diabetes after initiation of flash glucose monitoring in France: the RELIEF study. Diabetes Care. 2021;44(6):1368–76. https://doi.org/10.2337/dc20-1690.CrossRefPubMedPubMedCentral

23.

Wada E, Onoue T, Kobayashi T, et al. Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial. BMJ Open Diabetes Res Care. 2020;8:1 e001115. https://doi.org/10.1136/bmjdrc-2019-001115.CrossRefPubMed

24.

Elliott T, Beca S, Beharry R, Tsoukas MA, Zarruk A, Abitbol A. The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: a retrospective real-world chart review study. Diab Vasc Dis Res. 2021;18(4):14791641211021374. https://doi.org/10.1177/14791641211021374.CrossRefPubMedPubMedCentral

25.

Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1):55–73. https://doi.org/10.1007/s13300-016-0223-6.CrossRefPubMed

26.

Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167(6):365–74. https://doi.org/10.7326/M16-2855.CrossRefPubMed

27.

Martens T, Beck RW, Bailey R, et al. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA. 2021;325(22):2262–72. https://doi.org/10.1001/jama.2021.7444.CrossRefPubMed

28.

Yaron M, Roitman E, Aharon-Hananel G, et al. Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Diabetes Care. 2019;42(7):1178–84. https://doi.org/10.2337/dc18-0166.CrossRefPubMed

29.

Ehrhardt N, Al ZE. Continuous glucose monitoring as a behavior modification tool. Clin Diabetes. 2020;38(2):126–31. https://doi.org/10.2337/cd19-0037.CrossRefPubMedPubMedCentral

30.

Aronson R, Brown RE, Chu L, et al. Impact of flash glucose monitoring in people with type 2 diabetes inadequately controlled with non-insulin antihyperglycaemic therapy (IMMEDIATE): a randomized controlled trial. Diabetes Obes Metab. 2023;25(4):1024–31. https://doi.org/10.1111/dom.14949.CrossRefPubMed

31.

InPen User Guide. https://www.medtronicdiabetes.com/sites/default/files/library/download-library/user-guides/InPen-user-guide.pdf Accessed 20 Nov 2023

32.

MacLeod J, Im GH, Smith M, Vigersky RA. Shining the spotlight on multiple daily insulin therapy: real-world evidence of the InPen™ smart insulin pen. Diabetes Technol Ther. 2023 https://doi.org/10.1089/dia.2023.0365. https://doi.org/10.1089/dia.2023.0365

33.

Tempo Smart Button User Guide. https://pi.lilly.com/us/tempo-smart-button-ug.pdf Accessed 2 Dec 2023

34.

Bigfoot Unity System User Guide. https://f.hubspotusercontent40.net/hubfs/5085144/PDFs/Bigfoot%20Unity%E2%84%A2%20System%20User%20Guide.pdf. Accessed 2 Dec 2023

35.

ClinicalTrials.Gov. https://clinicaltrials.gov/study/NCT05088265?term=NCT05088265. Accessed 9 Dec 2023

36.

Malone JK, Beck R, Tillman J, et al. 936-P:Three-month interim analysis from the prospective Bigfoot Unity Real World Study (BURST). Diabetes. 2023; 72(Supplement_1): 936–P https://doi.org/10.2337/db23-936-P

37.

Galindo RJ, Ramos C, Cardona S, et al. Efficacy of a smart insulin pen cap for the management of patients with uncontrolled type 2 diabetes: a randomized cross-over trial. J Diabetes Sci Technol. 2023;17(1):201–7. https://doi.org/10.1177/19322968211033837.CrossRefPubMed

38.

Ananthanarayanan V, Mithun Haridas TP, Naveen R, et al. Reliable and affordable embedded system solution for continuous blood glucose maintaining system with wireless connectivity to blood glucose measuring system. IJCA Proceedings on Amrita International Conference of Women in Computing. 2013; AICWIC(2):36–43

39.

Reznik Y, Cohen O, Aronson R, et al. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet. 2014;384(9950):1265–72. https://doi.org/10.1016/S0140-6736(14)61037-0.CrossRefPubMed

40.

Boughton CK, Hovorka R. Automated insulin delivery in adults. Endocrinol Metab Clin North Am. 2020;49(1):167–78. https://doi.org/10.1016/j.ecl.2019.10.007.CrossRefPubMed

41.

•• Phillip M, Nimri R, Bergenstal RM, et al. Consensus recommendations for the use of automated insulin delivery technologies in clinical practice Endocr Rev 2023;44(2):254–280. https://doi.org/10.1210/endrev/bnac022. This article provides an in-depth data about the evidence of AID use, practical tips on initiating AID, and user training tips.

42.

V-Go User Guide. https://www.go-vgo.com/wp-content/uploads/2020/09/ART-1361-rev.B-V-Go-IFU.pdf. Accessed 2 Dec 2023

43.

Cziraky MJ, Abbott S, Nguyen M, et al. A pragmatic clinical trial to compare the real-world effectiveness of V-Go versus standard delivery of insulin in patients with advanced type 2 diabetes. J Health Econ Outcomes Res. 2019 6(2):70–83. https://doi.org/10.36469/9731

44.

Hundal R, Kowalyk S, Wakim A, Nikkel C, Sink Ii JH, Doyle M Multicenter real-world assessment of the effectiveness of V-Go wearable insulin delivery device in adult patients with type 2 diabetes (ENABLE Study): a retrospective analysis. Med Devices (Auckl). 2020;13:283–291 https://doi.org/10.2147/MDER.S265869

45.

Grunberger G, Rosenfeld CR, Bode BW, et al. Effectiveness of V-Go® for patients with type 2 diabetes in a real-world setting: a prospective observational study. Drugs Real World Outcomes. 2020;7(1):31–40. https://doi.org/10.1007/s40801-019-00173-8.CrossRefPubMed

46.

Cequr Simplicity user guide. https://myceqursimplicity.com/wp-content/uploads/User-Guide.pdf. Accessed 3 Dec 2023

47.

Bergenstal RM, Peyrot M, Dreon DM, et al. Implementation of basal-bolus therapy in type 2 diabetes: a randomized controlled trial comparing bolus insulin delivery using an insulin patch with an insulin pen. Diabetes Technol Ther. 2019;21(5):273–85. https://doi.org/10.1089/dia.2018.0298.CrossRefPubMedPubMedCentral

48.

Bergenstal RM, Johnson ML, Aroda VR, et al. Comparing patch vs pen bolus insulin delivery in type 2 diabetes using continuous glucose monitoring metrics and profiles. J Diabetes Sci Technol. 2022;16(5):1167–73. https://doi.org/10.1177/19322968211016513.CrossRefPubMed

49.

Zraick V, Dreon D, Naik R, et al. Patient user experience evaluation of bolus patch insulin delivery system. https://www.jnj.com/sites/default/files/pdf/ada-mae-poster-5-23-16_final.pdf. Accessed 2 Dec 2023

50.

Isaacs D, Kruger DF, Shoger E, Chawla H. Patient perceptions of satisfaction and quality of life regarding use of a novel insulin delivery device. Clin Diabetes. 2023;41(2):198–207. https://doi.org/10.2337/cd22-0034.CrossRefPubMed

51.

Omnipod GO^TM. https://www.omnipod.com/what-is-omnipod/omnipod-go. Accessed 2 Dec 2023

52.

Tandem T. Slim X2 user guide. https://www.tandemdiabetes.com/docs/default-source/user-guide/aw-1007704_b-user-guide-mobile-bolus-tslim-x2-control-iq-7-6-mgdl-artwork-weba4e76d9775426a79a519ff0d00a9fd39.pdf?sfvrsn=18a507d7_231. Accessed 3 Dec 2023

53.

Forlenza GP, Carlson AL, Galindo RJ, et al. Real-world evidence supporting tandem control-IQ hybrid closed-loop success in the medicare and medicaid type 1 and type 2 diabetes populations. Diabetes Technol Ther. 2022;24(11):814–23. https://doi.org/10.1089/dia.2022.0206.CrossRefPubMedPubMedCentral

54.

Habif S, Constantin A, Mueller L, et al. 126-LB: glycemic outcomes for people with type 1 and type 2 diabetes using control-IQ technology: real-world data from early adopters. Diabetes. 2020, 69(Supplement_1): 126–LB https://doi.org/10.2337/db20-126-lb

55.

ClinicalTrials.Gov. https://clinicaltrials.gov/study/NCT04233229. Accessed 9 Dec 2023

56.

ClinicalTrials.Gov.https://clinicaltrials.gov/study/NCT06024928. Accessed 9 Dec 2023

57.

ClinicalTrials.Gov.https://clinicaltrials.gov/study/NCT05785832. Accessed 9 Dec 2023

58.

Medtronic MiniMed 780G User Guide. https://www.medtronicdiabetes.com/sites/default/files/library/download-library/user-guides/MiniMed-780G-system-user-guide-with-Guardian-4-sensor.pdf. Accessed 3 Dec 2023

59.

What is Meal Detection^TM technology?. The LOOP Blog. Published July 19, 2023. https://www.medtronicdiabetes.com/loop-blog/meal-detection-technology/. Accessed 9 Dec 2023

60.

ClinicalTrials.Gov. https://clinicaltrials.gov/study/NCT05238142. Accessed 9 Dec 2023

61.

Omnipod 5 User Guide. https://www.omnipod.com/sites/default/files/Omnipod-5_User-guide.pdf. Accessed 3 Dec 2023

62.

Davis GM, Peters AL, Bode BW, et al. Safety and efficacy of the Omnipod 5 automated insulin delivery system in adults with type 2 diabetes: from injections to hybrid closed-loop therapy. Diabetes Care. 2023;46(4):742–50. https://doi.org/10.2337/dc22-1915.CrossRefPubMedPubMedCentral

63.

BetaBionics iLet User Guide. https://www.betabionics.com/wp-content/uploads/LA000079_C-iLet-Bionic-Pancreas-System-HCP-Guide.pdf. Accessed 2 Dec 2023

64.

Peters AL, Ahmann AJ, Hirsch IB, Raymond JK. Advances in glucose monitoring and automated insulin delivery: supplement to Endocrine Society clinical practice guidelines. J Endocr Soc. 2018;2(11):1214–25. https://doi.org/10.1210/js.2018-00262.CrossRefPubMedPubMedCentral

65.

Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract. 2021;27(6):505–37. https://doi.org/10.1016/j.eprac.2021.04.008.CrossRefPubMed

66.

Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update. Endocr Pract. 2022;28(10):923–1049. https://doi.org/10.1016/j.eprac.2022.08.002.CrossRefPubMedPubMedCentral

67.

•• ElSayed NA, Aleppo G, Aroda VR, et al. on behalf of the American Diabetes Association. 7. Diabetes technology: standards of care in diabetes—2023. Diabetes Care. 2023; 46(Supplement_1): S111–S127. https://doi.org/10.2337/dc23-S007. Extensive guideline recommendation on the use of diabetes technology.

68.

•• Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update. Endocr Pract. 2023;29(5):305–340. https://doi.org/10.1016/j.eprac.2023.02.001. Extensive guideline recommendation on the use of diabetes technology.

Titel: Diabetes Technology in People with Type 2 Diabetes: Novel Indications
verfasst von: Shubham Agarwal
Rodolfo J. Galindo
Amy V. Shah
Marconi Abreu
Publikationsdatum: 29.02.2024
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 5/2024
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-024-01536-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Diabetes Technology in People with Type 2 Diabetes: Novel Indications

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin